Global Car T-cell Therapy Market 2024-2028

Global Car T-Cell Therapy Market 2024-2028

The car t-cell therapy market is forecasted to grow by USD 3027.1 mn during 2023-2028, accelerating at a CAGR of 16.83% during the forecast period. The report on the car t-cell therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by growing awareness regarding car t-cell therapy, increasing prevalence of blood cancer, and increasing incidence of hematological malignancies.

Technavio's car t-cell therapy market is segmented as below:

ByEnd-user

• Hospitals
• Cancer treatment centers

ByType

• CD19
• CD22
• BCMA
• Others

ByGeography

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the rising number of product approvals and clinical trials related to car t- cell therapy as one of the prime reasons driving the car t-cell therapy market growth during the next few years. Also, growing investments in research and development to remodel design of car-t therapy and growing number of collaborations and partnerships will lead to sizable demand in the market.

The report on the car t-cell therapy market covers the following areas:

• Car t-cell therapy market sizing
• Car t-cell therapy market forecast
• Car t-cell therapy market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading car t-cell therapy market vendors that include ACROBIOSYSTEMS INC., Allogene Therapeutics Inc., Autolus Therapeutics plc, Bristol Myers Squibb Co., Celyad Oncology SA, Eli Lilly and Co., Fate Therapeutics Inc., Fortress Biotech Inc., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Merck KGaA, Miltenyi Biotec B.V. and Co. KG, Noile Immune Biotech Inc., Novartis AG, Pfizer Inc., Sangamo Therapeutics Inc, Sorrento Therapeutics Inc., and TCR2 Therapeutics Inc.. Also, the car t-cell therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.